Investor Presentation

AI summary - Revenue grew 12.9% YoY to INR 4,031 Cr in Q1 FY27; EBITDA margin improved 250 bps to 26.3% - Domestic business (ex Consumer Healthcare) grew 11% YoY led by strong chronic segment growth: cardiac +19.4%, anti-diabetes +12.7% - Exports business grew 29% YoY; Consumer Healthcare segment grew 4% YoY - Gross margin improved 230 bps YoY to 72.8%; PAT margin up 170 bps to 14.2% - Net debt reduced to INR 3,377 Cr; Net debt/Adj. EBITDA improved to 0.9x - Chronic therapies outperformed market with 1.1x growth in cardiac and anti-diabetes; specialty and super specialty segments expanding - Consumer Healthcare brands maintained leadership with strong market shares in key categories - Capex as % of revenue at 4.3%; ROCE at 13% on TTM basis - Q1 FY27 earnings call scheduled on July 30, 2026, 6:30 PM IST